On October 28, 2025, Kalaris Therapeutics, Inc. appointed Matthew Gall as Chief Financial Officer and Treasurer, effective November 3, 2025, with an annual salary of $485,000 and a potential bonus of up to 40%. He will also receive stock options for 235,000 shares that vest over time, as part of his employment agreement.